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Pluripotency and tumorgenicity appear fundamentally linked. Recent investigations into the role of
PARylation in chromatin remodeling (Ahel et al., 2009; Gottschalk et al., 2009), combinedwith the demonstra-
tion that p53 serves as a barrier to pluripotency (Banito et al., 2009), further strengthen this connection.The accurate repair of DNA damage is
crucial for the maintenance of genome
integrity and the prevention of tumors. A
pair of recent studies in Science (Ahel
et al., 2009) and PNAS (Gottschalk et al.,
2009) reveals that the chromatin remodel-
ing factor ‘‘Amplified in Liver Cancer 1’’
(Alc1, also known as ‘‘Chromodomain
helicase DNA binding protein 1-like’’
[Chd1L]) may participate in the initiation
of cancer. Alc1 belongs to the SNF2
gene family and is found in excessive
amounts in 50% of liver cancers. Alc1
normally loosens tightly packaged chro-
matin to allow for repair of DNA damage.
In cancer cells, however, too much
ALC1 can overly relax the chromatin,
making the DNA vulnerable to mistakes
and thus raising the risk of cancer.
Furthermore, a recent Nature study
reports that an additional SNF2 family
member, Chd1, plays an essential role in
the regulation of embryonic stem cell
(ESC) pluripotency (Gaspar-Maia et al.,
2009). Combined, the trio of studies
underscores the importance of DNA
repair systems to both stem cells and
tumors and highlight potential mecha-
nistic similarities between the processes
regulating pluripotency and oncogenesis.
Alc1 is activated by poly(ADP-ribose)
(PAR) polymerase-1 (PARP-1), a DNA
nick sensor enzyme that is activated by
DNA breaks, during the posttranslational
modification process termed ‘‘PARyla-
tion.’’ Activated PARP-1 cleaves NAD
into nicotinamide and ADP-ribose and
covalently attaches a PAR polymer to it-
self and other suitable protein substrates.
PARP-1 and PAR are well known to play
critical roles in chromatin organization,
transcriptional regulation, and DNA repli-
cation and repair, but their underlyingmechanism of action remains largely
unclear. The recent demonstration that
PARP-1 and PAR recruit and activate the
chromatin remodeler Alc1 (Ahel et al.,
2009; Gottschalk et al., 2009) suggests
a mechanism by which they may function.
Furthermore, Alc1 activity can be blocked
by PARP-1 inhibitors, which have already
been explored for use in cancer treat-
ment, suggesting that the therapeutic
activities of PARP-1 inhibitors may be
due in part to indirect effects on Alc1.
Together, these studies identify a new
function of the SNF2 family member Alc1
(Chd1L) in cancer.
In addition to this new role in oncogen-
esis, another SNF2 gene family has been
shown to influence pluripotency (Gas-
par-Maia et al., 2009). In this case, Chd1
seems to act by keeping chromatin in an
open configuration and thus poised to
express genes essential for maintaining
‘‘stemness.’’ Importantly, Chd1 also influ-
ences the reprogramming of somatic
cells back to a pluripotent state, in that
inhibition or depletion of Chd1 hinders
the generation of induced pluripotent
stem cells (iPSCs) from adult cells. Deter-
mination of what other molecules collabo-
rate with Chd1 to direct chromatin re-
modeling may aid efforts to increase the
efficiency and safety of iPSC generation
and may also shed new light on how cells
transition from one type to another,
a process that happens normally during
embryonic development and tends to go
astray in cancer. Given that Chd1L is
regulated by PARylation, it will be inter-
esting to investigate whether PARP-1
and PAR are also involved in Chd1-
mediated chromatin remodeling and how
the chromatin open state is maintained
by Chd1.Cell Stem CelIn contrast, an additional recent study
in Nature Structural and Molecular Bio-
logy shows that PARP-1 and PAR may
instead help to condense the chromatin
in response to DNA damage (Timinszky
et al., 2009). X-ray crystallography reveals
that when PARP-1 is activated by DNA
damage, select macrodomain proteins
rapidly detect and surround the resulting
PAR to envelop it in a snug pocket. The
histone macroH2A1.1 is one such PAR-
binding protein, and although histones
play a major role in assembling chromatin
and keeping it together, they do not
typically harbor macrodomains. Further-
more, cancer cells do not express mac-
roH2A1.1, and so given that mac-
roH2A1.1 normally helps to rapidly
detect DNA damage, this unusually modi-
fied histone may represent a ‘‘missing
link’’ in cancer. Because macroH2A1.1 is
embedded in chromatin, when it recog-
nizes PAR at DNA damage sites it drags
the complex but highly organized tangle
of chromatin with it. As a result, mac-
roH2A1.1 condenses the chromatin envi-
ronment around the damaged area. It is
possible that by temporarily compacting
the DNA, the broken ends of the DNA
molecule are kept closer together,
thereby increasing their opportunity for
repair. However, how this model might
explain the precise role of PARP-1 and
PAR in mediating chromatin plasticity,
not to mention pluripotency, remains to
be determined.
Recently, five papers appeared simul-
taneously in Nature that indicated that
the tumor suppressor p53 acts as a barrier
to induced pluripotency (discussed in
Krizhanovsky and Lowe, 2009), and such
a finding may also add to the evidence
connecting PARP-1 to pluripotency andl 5, October 2, 2009 ª2009 Elsevier Inc. 349
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Previewscancer. Specifically, inactivating or de-
leting p53 allows for a 100-fold in-
crease in iPSC reprogramming efficiency,
consistent with previous efforts that
utilized siRNA-mediated p53 knockdown
(Zhao et al., 2008). Another paper in
Genes and Development by Banito et al.
(2009) also shows that expression of the
four reprogramming factors (Oct4, Sox2,
Klf4, and c-Myc) triggers senescence
by upregulating p53, p16(INK4a), and
p21(CIP1), as a result of induction of
DNA damage response and chromatin
remodeling of the INK4a/ARF locus.
PARP-1 and p53 are well known to
interact both physically and functionally,
and the two proteins have been nick-
named the ‘‘guardians of the genome.’’
Gao and colleagues (2009) reveal that
PARylation promotes the differentiation
of pluripotent ESCs. Thus, it is reasonable
to speculate that PARP-1, like p53, may
impede somatic cell reprogramming
back to a pluripotent state. Clearly,
although already well studied, many of
the biological functions of the PARP-1/
p53 complex remain to be discovered.
The combination of recent studies raises
interesting questions and suggests that
further study of their enigmatic functions
may yield improved protocols for efficient
iPSC generation. For example, would
additional studies support the notion that
molecules critically involved in genome
stability, such as PARP-1 and p53, func-
tion as not only ‘‘guardians of the
genome,’’ but also ‘‘barriers to pluripo-
tency’’? Genome integrity may indeed
be a fundamental requirement for stem
cell pluripotency and reprogramming.
With the recent demonstration that iPSCs
pass the ultimate test for pluripotency and350 Cell Stem Cell 5, October 2, 2009 ª200in fact yield healthy, live mice via tetra-
ploid complementation (Zhao et al.,
2009; Kang et al., 2009; Boland et al.,
2009), part of the lingering concern
regarding the cancer risk of iPSCs would
appear somewhat pacified. However,
the collection of new findings discussed
above appears to strengthen, rather than
overcome, the fundamental link between
induced pluripotency and tumorgenicity.
It does appear that the major guardians
of the genome also serve as roadblocks
for iPSC generation and that simulta-
neous and systematic destruction of
these roadblocks may improve reprog-
ramming efficiency. But at what cost,
and will it be safe? Reprogramming
methods that include inactivation or dele-
tion of p53 allow even cells burdened with
heavy DNA damage to be turned into
stem cells. Although such methods may
not seem desirable (at least not for thera-
peutic use of iPSCs), this approach may
help to establish useful cellular models
for a variety of diseases in which the target
somatic cells have proven difficult to
reprogram. Of course, loss of p53 can
lead to transformation of the resulting
iPSCs, but this risk could be minimized
by restoring p53 expression once iPSCs
have been derived or by using chemical
inhibitors or other means to transiently
inactivate p53. Given that the efficiency of
cell reprogramming technologies remains
woefully low, any methods that help to
improve efficiency are likely to be of
tremendous practical use.
Altogether, the critical new insights
provided by this flurry of recent investiga-
tions that probe the roles of key players
involved in genome integrity and chro-
matin plasticity, and that address how9 Elsevier Inc.chromatin is kept ‘‘loose,’’ collectively
underscore the growing link that connects
the cancer and stem cell biology fields.
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